WallStSmart

DexCom Inc (DXCM)vsInspire Medical Systems Inc (INSP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 426% more annual revenue ($4.82B vs $915.25M). DXCM leads profitability with a 19.3% profit margin vs 14.3%. INSP trades at a lower P/E of 11.5x. DXCM earns a higher WallStSmart Score of 72/100 (B).

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.7Profit: 8.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.67

INSP

Buy

56

out of 100

Grade: C

Growth: 8.0Profit: 5.5Value: 8.3Quality: 9.0
Piotroski: 5/9Altman Z: 5.38
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DXCMUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$656.95

Current Price

$75.14

$581.81 discount

UndervaluedFair: $656.95Overvalued
INSPUndervalued (+84.8%)

Margin of Safety

+84.8%

Fair Value

$449.81

Current Price

$51.07

$398.74 discount

UndervaluedFair: $449.81Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 9.0/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

EPS GrowthGrowth
92.2%10/10

Earnings expanding 92.2% YoY

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

INSP5 strengths · Avg: 9.6/10
P/E RatioValuation
11.5x10/10

Attractively priced relative to earnings

EPS GrowthGrowth
308.4%10/10

Earnings expanding 308.4% YoY

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.3810/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

INSP3 concerns · Avg: 2.7/10
Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Market CapQuality
$1.53B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
-0.6%1/10

Operating margin of -0.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.

Bull Case : INSP

The strongest argument for INSP centers on P/E Ratio, EPS Growth, Debt/Equity.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Bear Case : INSP

The primary concerns for INSP are Revenue Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

DXCM profiles as a mature stock while INSP is a value play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.45 — expect wider price swings.

DXCM is growing revenue faster at 15.0% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 56/100), backed by strong 19.3% margins and 15.0% revenue growth. INSP offers better value entry with a 84.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Inspire Medical Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.

Want to dig deeper into these stocks?